2024-21960. Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024
Diversion Estimates for 2024 ( g )
Fentanyl 112 Hydrocodone 124,170 Hydromorphone 1,137 Oxycodone 263,236 Oxymorphone 165 Implementation of Semi-Annual Quota Allotment
For the 2024 quota year, DEA announced that it intended to allocate procurement quotas to DEA-registered manufacturers of schedule II controlled substances on a quarterly basis, in order to help DEA prevent shortages and be more nimble in its administration of the quota program. After the announcement, DEA met with several manufacturers to discuss the impact of that change. Numerous manufacturers asked DEA to consider allocating quotas semi-annually to assist with production planning and execution. DEA understands and appreciates the complexities of the supply chain. In light of the discussions with manufacturers, as well as meetings with FDA discussing their statutory obligations for drug availability to meet legitimate patients' needs, input from health associations in foreign countries, and consideration of the continuing issues with the supply chain in the aftermath of the COVID-19 pandemic, DEA determined that it would and will allocate procurement quotas for schedule II controlled substances on a semi-annual basis, except that it would and will allocate procurement quotas for injectable drug products containing schedule II controlled substances on an annual basis. DEA announced this change in a letter to DEA-registered manufacturers on April 29, 2024. No further change is being implemented at this time. DEA remains committed to ensuring that all patients with legitimate medical need can access appropriately prescribed medications that are manufactured domestically.
Proposed Adjustments for the 2024 Aggregate Production Quotas and Assessment of Annual Needs
DEA is proposing increases to the APQ for the following schedule I substances: psilocybin and psilocyn. These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA's support for research with schedule I controlled substances. The proposed increases reflect research and development needs as part of the process for seeking the FDA approval of new drug products.
DEA is proposing increases to the APQ for the following schedule II substances: noroxymorphone (for conversion), oripavine, and oxymorphone (for conversion). These proposed increases are necessary to meet manufacturing needs and increased consumption of naloxone products as standard treatment for opioid overdose. These substances are part of the synthesis pathway to manufacture naloxone products. On March 13, 2024, the “White House Challenge to Save Lives from Overdose” was announced in support of the Administration's Unity Agenda efforts to address the opioid overdose crisis.[11] The challenge is a nationwide initiative to increase training, awareness, and access to lifesaving opioid overdose reversal medications. The FDA has approved two over the counter (OTC) naloxone products for the emergency treatment of opioid overdose.[12] As a result of the White House Challenge and efforts by the Department of Health and Human Services to help recipients of State and Tribal Opioid Response Grants increase distribution of opioid overdose reversal agents, DEA is expecting medical usage of naloxone to continue to rise in 2024. The proposed increase to the APQ of noroxymorphone (for conversion), oripavine and oxymorphone (for conversion) reflects this increasing medical usage of naloxone.
DEA is proposing decreases to the following APQ: fentanyl, hydrocodone (for sale), hydromorphone, and oxycodone (for sale). These proposed decreases are based on adjustments to the diversion estimates for calendar year 2024.
DEA established the 2024 APQ for substances in schedules I and II on January 3, 2024.[13] Subsequent to that publication, DEA published in the Federal Register a final rule to permanently schedule 2-methyl AP-237 under the CSA.[14] As a result, this substance is subject to CSA schedule I controls and DEA is proposing to assign an individual APQ for this substance pursuant to 21 U.S.C. 826 and 21 CFR part 1303.
The Administrator, therefore, proposes to adjust the 2024 APQ for the schedule I and II controlled substances noroxymorphone (for conversion), oripavine, oxymorphone (for conversion), psilocybin, psilocyn, and 2-methyl AP-237. The proposed adjusted APQ and AAN, as expressed in grams of anhydrous acid or base, are as follows:
Basic class Established 2024 quotas (g) Proposed revised 2024 quotas (g) New Temporary Controlled Schedule I Substances 4F-MDMB-BUTICA 30 no change ( print page 78767) 5F-EDMB-PICA 30 no change ADB-4en-PINACA 30 no change Clonazolam 30 no change CUMYL-PEGACLONE 30 no change Diclazepam 30 no change Etizolam 30 no change Flualprazolam 30 no change Flubromazolam 30 no change MDMB-4en-PINACA 30 no change MMB-FUBICA 30 no change Schedule I -[1-(2-Thienyl)cyclohexyl]pyrrolidine 20 no change 1-(1-Phenylcyclohexyl)pyrrolidine 30 no change 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 10 no change 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) 30 no change 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) 30 no change 1-[1-(2-Thienyl)cyclohexyl]piperidine 15 no change 2′-fluoro 2-fluorofentanyl 30 no change 1-Benzylpiperazine 25 no change 1-Methyl-4-phenyl-4-propionoxypiperidine 10 no change 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 30 no change 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) 30 no change 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 30 no change 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) 30 no change 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 100 no change 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 30 no change 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) 30 no change 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 25 no change 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 30 no change 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 30 no change 2,5-Dimethoxy-4-ethylamphetamine (DOET) 25 no change 2,5-Dimethoxy-4-n-propylthiophenethylamine 25 no change 2,5-Dimethoxyamphetamine 25 no change 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) 30 no change 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) 30 no change 2-Methyl AP-237 0 30 3,4,5-Trimethoxyamphetamine 30 no change 3,4-Methylenedioxyamphetamine (MDA) 12,000 no change 3,4-Methylenedioxymethamphetamine (MDMA) 12,000 no change 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 40 no change 3,4-Methylenedioxy-N-methylcathinone (methylone) 5,200 no change 3,4-Methylenedioxypyrovalerone (MDPV) 35 no change 3-FMC; 3-Fluoro-N-methylcathinone 25 no change 3-Methylfentanyl 30 no change 3-Methylmethcathinone 30 no change 3-Methylthiofentanyl 30 no change 4,4′-Dimethylaminorex 30 no change 4-Bromo-2,5-dimethoxyamphetamine (DOB) 30 no change 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 5,100 no change 4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP) 25 no change 4-CN-Cumyl-Butinaca 25 no change 4-Fluoroisobutyryl fentanyl 30 no change 4F-MDMB-BINACA 30 no change 4-FMC; Flephedrone 25 no change 4-MEC; 4-Methyl-N-ethylcathinone 25 no change 4-Methoxyamphetamine 150 no change 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (alpha-PiHP) 30 no change 4-Methyl-2,5-dimethoxyamphetamine (DOM) 25 no change 4-Methylaminorex 25 no change 4-Methyl-N-methylcathinone (mephedrone) 45 no change 4-Methyl-alpha-ethylaminopentiophenone (4-MEAP) 25 no change 4-Methyl-alpha-pyrrolidinohexiophenone (MPHP) 25 no change 4′-Methyl acetyl fentanyl 30 no change 4-Methyl-α-pyrrolidinopropiophenone (4-MePPP) 25 no change 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 50 no change 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 40 no change 5F-AB-PINACA; (1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 25 no change ( print page 78768) 5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 25 no change 5F-CUMYL-P7AICA; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3carboximide 25 no change 5F-CUMYL-PINACA 25 no change 5F-EDMB-PINACA 25 no change 5F-MDMB-PICA 25 no change 5F-AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) 25 no change 5F-APINACA; 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) 25 no change 5-Fluoro-PB-22; 5F-PB-22 25 no change 5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 25 no change 5-Methoxy-3,4-methylenedioxyamphetamine 25 no change 5-Methoxy-N,N-diisopropyltryptamine 25 no change 5-Methoxy-N,N-dimethyltryptamine 11,000 no change AB-CHMINACA 30 no change AB-FUBINACA 50 no change AB-PINACA 30 no change ADB-BUTINACA 30 no change ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) 30 no change Acetorphine 25 no change Acetyl Fentanyl 100 no change Acetyl-alpha-methylfentanyl 30 no change Acetyldihydrocodeine 30 no change Acetylmethadol 25 no change Acryl Fentanyl 25 no change ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) 50 no change AH-7921 30 no change All other tetrahydrocannabinol 1,166,130 no change Allylprodine 25 no change Alphacetylmethadol 25 no change alpha-Ethyltryptamine 25 no change Alphameprodine 25 no change Alphamethadol 25 no change alpha-Methylfentanyl 30 no change alpha-Methylthiofentanyl 30 no change alpha-Methyltryptamine (AMT) 25 no change alpha-Pyrrolidinobutiophenone (α-PBP) 25 no change alpha-pyrrolidinoheptaphenone (PV8) 25 no change alpha-pyrrolidinohexabophenone (alpha-PHP) 25 no change alpha-Pyrrolidinopentiophenone (α-PVP) 25 no change Amineptine 30 no change Aminorex 25 no change Anileridine 20 no change APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) 25 no change Benzethidine 25 no change Benzylmorphine 30 no change Betacetylmethadol 25 no change beta-Hydroxy-3-methylfentanyl 30 no change beta-Hydroxyfentanyl 30 no change beta-Hydroxythiofentanyl 30 no change beta-Methyl fentanyl 30 no change beta′-Phenyl fentanyl 30 no change Betameprodine 25 no change Betamethadol 4 no change Betaprodine 25 no change Brorphine 30 no change Bufotenine 15 no change Butonitazene 30 no change Butylone 25 no change Butyryl fentanyl 30 no change Cathinone 40 no change Clonitazene 25 no change Codeine methylbromide 30 no change Codeine-N-oxide 192 no change Crotonyl Fentanyl 25 no change Cyclopentyl Fentanyl 30 no change Cyclopropyl Fentanyl 20 no change Cyprenorphine 25 no change d-9-THC 1,523,040 no change Desomorphine 25 no change Dextromoramide 25 no change Diapromide 20 no change Diethylthiambutene 20 no change ( print page 78769) Diethyltryptamine 25 no change Difenoxin 9,300 no change Dihydromorphine 639,954 no change Dimenoxadol 25 no change Dimepheptanol 25 no change Dimethylthiambutene 20 no change Dimethyltryptamine 11,000 no change Dioxyaphetyl butyrate 25 no change Dipipanone 25 no change Drotebanol 25 no change Ethylmethylthiambutene 25 no change Ethylone 25 no change Etodesnitazene 30 no change Etonitazene 25 no change Etorphine 30 no change Etoxeridine 25 no change Eutylone 30 no change Fenethylline 30 no change Fentanyl carbamate 30 no change Fentanyl related substances 600 no change Flunitazene 30 no change FUB-144 25 no change FUB-AKB48 25 no change Fub-AMB, MMB-Fubinaca, AMB-Fubinaca 25 no change Furanyl fentanyl 30 no change Furethidine 25 no change gamma-Hydroxybutyric acid 29,417,000 no change Heroin 150 no change Hydromorphinol 40 no change Hydroxypethidine 25 no change Ibogaine 150 no change Isobutyryl Fentanyl 25 no change Isotonitazine 25 no change JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 no change JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 no change JWH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 no change JWH-081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) 30 no change JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) 30 no change JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) 35 no change JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) 30 no change JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) 30 no change JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) 30 no change Ketobemidone 30 no change Levomoramide 25 no change Levophenyacylmorphan 25 no change Lysergic acid diethylamide (LSD) 1,200 no change MAB-CHMINACA; ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) 30 no change MDMB-CHMICA; MMB-CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) 30 no change MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 30 no change MMB-CHMICA-(AMB-CHIMCA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate 25 no change Marijuana 6,675,000 no change Marijuana extract 1,000,000 no change Mecloqualone 30 no change Mescaline 1,200 no change Mesocarb 30 no change Methaqualone 60 no change Methcathinone 25 no change Methiopropamine 30 no change Methoxetamine 30 no change Methoxyacetyl fentanyl 30 no change Methyldesorphine 5 no change Methyldihydromorphine 25 no change Metodesnitazene 30 no change Metonitazene 30 no change Morpheridine 25 no change Morphine methylbromide 5 no change Morphine methylsulfonate 5 no change Morphine-N-oxide 150 no change MT-45 30 no change ( print page 78770) Myrophine 25 no change NM2201: Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3-carboxylate 25 no change N,N-Dimethylamphetamine 25 no change Naphyrone 25 no change N-Ethyl-1-phenylcyclohexylamine 25 no change N-Ethyl-3-piperidyl benzilate 10 no change N-Ethylamphetamine 24 no change N-Ethylhexedrone 25 no change N-Ethylpentylone, ephylone 30 no change N-Hydroxy-3,4-methylenedioxyamphetamine 24 no change Nicocodeine 25 no change Nicomorphine 25 no change N-methyl-3-piperidyl benzilate 30 no change N-Pyrrolidino Etonitazene 30 no change Noracymethadol 25 no change Norlevorphanol 2,550 no change Normethadone 25 no change Normorphine 40 no change Norpipanone 25 no change Ocfentanil 25 no change ortho-Fluoroacryl fentanyl 30 no change ortho-Fluorobutyryl fentanyl 30 no change Ortho-Fluorofentanyl,2-Fluorofentanyl 30 no change ortho-Fluoroisobutyryl fentanyl 30 no change ortho-Methyl acetylfentanyl 30 no change ortho-Methyl methoxyacetyl fentanyl 30 no change Para-Chlorisobutyrl fentanyl 30 no change Para-flourobutyryl fentanyl 25 no change Para-fluorofentanyl 25 no change para-Fluoro furanyl fentanyl 30 no change Para-Methoxybutyrl fentanyl 30 no change Para-methoxymethamphetamine 30 no change para-Methylfentanyl 30 no change Parahexyl 5 no change PB-22; QUPIC 20 no change Pentedrone 25 no change Pentylone 25 no change Phenadoxone 25 no change Phenampromide 25 no change Phenomorphan 25 no change Phenoperidine 25 no change Phenyl fentanyl 30 no change Pholcodine 5 no change Piritramide 25 no change Proheptazine 25 no change Properidine 25 no change Propiram 25 no change Protonitazene 30 no change Psilocybin 20,000 30,000 Psilocyn 24,000 36,000 Racemoramide 25 no change SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) 45 no change SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) 30 no change Tetrahydrofuranyl fentanyl 15 no change Thebacon 25 no change Thiafentanil 25 no change Thiofentanyl 25 no change Thiofuranyl fentanyl 30 no change THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) 30 no change Tilidine 25 no change Trimeperidine 25 no change UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 25 no change U-47700 30 no change Valeryl fentanyl 25 no change Zipeprol 30 no change Schedule II 1-Phenylcyclohexylamine 15 no change 1-Piperidinocyclohexanecarbonitrile 25 no change 4-Anilino-N-phenethyl-4-piperidine (ANPP) 937,874 no change ( print page 78771) Alfentanil 5,000 no change Alphaprodine 25 no change Amobarbital 20,100 no change Bezitramide 25 no change Carfentanil 20 no change Cocaine 60,492 no change Codeine (for conversion) 942,452 no change Codeine (for sale) 19,262,957 no change d-amphetamine (for sale) 21,200,000 no change d,l-amphetamine 21,200,000 no change d-amphetamine (for conversion) 23,688,235 no change Dexmethylphenidate (for sale) 6,200,000 no change Dexmethylphenidate (for conversion) 5,374,683 no change Dextropropoxyphene 35 no change Dihydrocodeine 115,227 no change Dihydroetorphine 25 no change Diphenoxylate (for conversion) 14,100 no change Diphenoxylate (for sale) 770,800 no change Ecgonine 60,492 no change Ethylmorphine 30 no change Etorphine hydrochloride 32 no change Fentanyl 731,360 731,341 Glutethimide 25 no change Hydrocodone (for conversion) 1,250 no change Hydrocodone (for sale) 27,143,545 27,121,498 Hydromorphone 1,951,801 1,951,508 Isomethadone 30 no change L-amphetamine 30 no change Levo-alphacetylmethadol (LAAM) 25 no change Levomethorphan 30 no change Levorphanol 20,000 no change Lisdexamfetamine 32,736,000 no change Meperidine 681,184 no change Meperidine Intermediate-A 30 no change Meperidine Intermediate-B 30 no change Meperidine Intermediate-C 30 no change Metazocine 15 no change Methadone (for sale) 25,619,700 no change Methadone Intermediate 27,673,600 no change d,l-Methamphetamine 150 no change d-methamphetamine (for conversion) 485,020 no change d-methamphetamine (for sale) 47,000 no change l-methamphetamine 587,229 no change Methylphenidate (for sale) 53,283,000 no change Methylphenidate (for conversion) 19,975,468 no change Metopon 25 no change Moramide-intermediate 25 no change Morphine (for conversion) 2,393,200 no change Morphine (for sale) 20,805,957 no change Nabilone 62,000 no change Norfentanyl 25 no change Noroxymorphone (for conversion) 22,044,741 24,756,979 Noroxymorphone (for sale) 1,000 no change Oliceridine 25,100 no change Opium (powder) 250,000 no change Opium (tincture) 530,837 no change Oripavine 33,010,750 37,721,950 Oxycodone (for conversion) 437,827 no change Oxycodone (for sale) 53,658,226 53,584,449 Oxymorphone (for conversion) 28,204,371 31,773,105 Oxymorphone (for sale) 464,464 no change Pentobarbital 40,000,000 no change Phenazocine 25 no change Phencyclidine 35 no change Phenmetrazine 25 no change Phenylacetone 100 no change Piminodine 25 no change Racemethorphan 5 no change Racemorphan 5 no change Remifentanil 3,000 no change Secobarbital 172,100 no change ( print page 78772) Sufentanil 4,000 no change Tapentadol 10,390,226 no change Thebaine 57,137,944 no change List I Chemicals Ephedrine (for conversion) 41,100 no change Ephedrine (for sale) 3,933,336 no change Phenylpropanolamine (for conversion) 14,878,320 no change Phenylpropanolamine (for sale) 7,990,000 no change Pseudoephedrine (for conversion) 1,000 no change Pseudoephedrine (for sale) 186,617,466 no change
Document Information
- Published:
- 09/25/2024
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice with request for comments.
- Document Number:
- 2024-21960
- Dates:
- Interested persons may file written comments on this notice in accordance with 21 CFR 1303.13(c) and 1315.13(d). Electronic comments must be submitted, and written comments must be postmarked, on or before October 25, 2024. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
- Pages:
- 78764-78772 (9 pages)
- Docket Numbers:
- Docket No. DEA-1228A
- PDF File:
- 2024-21960.pdf